Boehringer presents phase III results of adalimumab biosimilar candidate to HUMIRA
Boehringer Ingelheim announced results from the pivotal Phase III VOLTAIRE-RA study, confirming that its adalimumab biosimilar candidate BI 695501 and HUMIRA have similar efficacy,…
Read More...
Read More...